BBOT · BridgeBio Oncology Therapeutics Inc
United States · RS rating 3 · As of 2026-10-14
| Price | 2.90 USD |
|---|---|
| 1-day change | -1.5% |
| RS rating (overall / 1M / 3M / 12M) | 3 / 3 / 3 / 8 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 15 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +52.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +78.8% |
| Market cap (USD) | $717.9M |